NZ604831A - Apoptosis signal-regulating kinase inhibitors - Google Patents
Apoptosis signal-regulating kinase inhibitorsInfo
- Publication number
- NZ604831A NZ604831A NZ604831A NZ60483111A NZ604831A NZ 604831 A NZ604831 A NZ 604831A NZ 604831 A NZ604831 A NZ 604831A NZ 60483111 A NZ60483111 A NZ 60483111A NZ 604831 A NZ604831 A NZ 604831A
- Authority
- NZ
- New Zealand
- Prior art keywords
- diseases
- cyclopropyl
- triazol
- thiophen
- thiazol
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000017169 kidney disease Diseases 0.000 abstract 2
- TWKCRNSVEUJXBT-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[5-[4-(3-hydroxybutan-2-yl)-1,2,4-triazol-3-yl]thiophen-3-yl]pyridine-2-carboxamide Chemical compound CC(O)C(C)N1C=NN=C1C1=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=CS1 TWKCRNSVEUJXBT-UHFFFAOYSA-N 0.000 abstract 1
- IMLYDRHZHDRSMD-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-n-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-2-fluorobenzamide Chemical compound FC1=CC=C(N2C=C(N=C2)C2CC2)C=C1C(=O)NC(N=1)=CSC=1C1=NN=CN1C1CC1 IMLYDRHZHDRSMD-UHFFFAOYSA-N 0.000 abstract 1
- OXBWEFYXJCXFOR-UHFFFAOYSA-N 5-(6-cyclopropylpyridin-3-yl)-n-[5-(4-cyclopropyl-1,2,4-triazol-3-yl)thiophen-3-yl]-2-methoxybenzamide Chemical compound COC1=CC=C(C=2C=NC(=CC=2)C2CC2)C=C1C(=O)NC(C=1)=CSC=1C1=NN=CN1C1CC1 OXBWEFYXJCXFOR-UHFFFAOYSA-N 0.000 abstract 1
- 229940127254 ASK1 inhibitor Drugs 0.000 abstract 1
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- LKFHDVNDOWOQLU-UHFFFAOYSA-N n-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(N=1)=CSC=1C1=NN=CN1C1CC1 LKFHDVNDOWOQLU-UHFFFAOYSA-N 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36108010P | 2010-07-02 | 2010-07-02 | |
| PCT/US2011/042694 WO2012003387A1 (en) | 2010-07-02 | 2011-06-30 | Apoptosis signal-regulating kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ604831A true NZ604831A (en) | 2014-12-24 |
Family
ID=44318106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ604831A NZ604831A (en) | 2010-07-02 | 2011-06-30 | Apoptosis signal-regulating kinase inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8440665B2 (enExample) |
| EP (1) | EP2588475B1 (enExample) |
| JP (1) | JP5705314B2 (enExample) |
| KR (1) | KR101759759B1 (enExample) |
| CN (1) | CN102985418B (enExample) |
| AU (1) | AU2011272782B2 (enExample) |
| BR (1) | BR112012033715A2 (enExample) |
| CA (1) | CA2802743C (enExample) |
| EA (1) | EA023040B1 (enExample) |
| ES (1) | ES2543428T3 (enExample) |
| IL (2) | IL223556A (enExample) |
| MX (1) | MX2012015105A (enExample) |
| NZ (1) | NZ604831A (enExample) |
| PL (1) | PL2588475T3 (enExample) |
| PT (1) | PT2588475E (enExample) |
| SI (1) | SI2588475T1 (enExample) |
| WO (1) | WO2012003387A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5693452B2 (ja) | 2008-08-04 | 2015-04-01 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法 |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| US8883785B2 (en) | 2010-01-25 | 2014-11-11 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| CN102985418B (zh) * | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| US9428464B2 (en) | 2011-08-30 | 2016-08-30 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| CA2844128C (en) | 2011-08-30 | 2020-09-01 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| AU2015201188B2 (en) * | 2012-01-27 | 2016-12-15 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitor |
| UY34573A (es) * | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| EP3632208A1 (en) | 2013-06-13 | 2020-04-08 | Biomatrica, INC. | Cell stabilization |
| WO2015095059A1 (en) * | 2013-12-20 | 2015-06-25 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015187499A1 (en) | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
| WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
| CR20170061A (es) | 2014-07-17 | 2017-07-17 | Chdi Foundation Inc | Métodos y composiciones para el tratamiento de trastornos relacionados con vih |
| TW201618781A (zh) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
| SG11201701723XA (en) | 2014-09-24 | 2017-04-27 | Gilead Sciences Inc | Methods of treating liver disease |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| WO2016106384A1 (en) | 2014-12-23 | 2016-06-30 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| ES3037826T3 (en) | 2015-12-08 | 2025-10-07 | Biomatrica Inc | Reduction of erythrocyte sedimentation rate |
| AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| FR3050112B1 (fr) | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
| WO2018090869A1 (zh) * | 2016-11-16 | 2018-05-24 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
| CN111094250B (zh) | 2017-03-03 | 2022-11-04 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法 |
| WO2018218042A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218044A2 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019034096A1 (en) * | 2017-08-17 | 2019-02-21 | Sunshine Lake Pharma Co., Ltd. | FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE |
| WO2019046186A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
| US10370352B2 (en) | 2017-09-07 | 2019-08-06 | Eli Lilly And Company | Cyclobutyl-imidazolidinone compounds |
| WO2019047094A1 (en) * | 2017-09-07 | 2019-03-14 | Eli Lilly And Company | CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS |
| CN111315380A (zh) * | 2017-09-08 | 2020-06-19 | 弗朗塞拉美国制药有限责任公司 | 凋亡信号调节激酶抑制剂及其用途 |
| CN111518080A (zh) * | 2017-10-12 | 2020-08-11 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
| WO2019099703A1 (en) * | 2017-11-16 | 2019-05-23 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
| WO2019134680A1 (zh) * | 2018-01-05 | 2019-07-11 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
| CN110294742B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 并环类ask1抑制剂及其应用 |
| US10919911B2 (en) | 2018-04-12 | 2021-02-16 | Terns, Inc. | Tricyclic ASK1 inhibitors |
| CN110407806B (zh) | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| AU2019262016B2 (en) | 2018-05-02 | 2024-07-11 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| JP2021534152A (ja) * | 2018-08-14 | 2021-12-09 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Ａｓｋ１阻害剤 |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| CN111018831B (zh) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | 细胞凋亡信号调节激酶抑制剂及其应用 |
| WO2021127643A1 (en) * | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| IL298475A (en) * | 2020-06-09 | 2023-01-01 | Anima Biotech Inc | Collagen-1 translation inhibitors and methods of their use |
| TW202220967A (zh) * | 2020-07-24 | 2022-06-01 | 美商伊尼製藥股份有限公司 | 噻吩hsd17b13抑制劑及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| CA1121825A (en) * | 1978-04-11 | 1982-04-13 | Franco Bolasco | 2-(2-thenoylthio)-propionylglycine: method for its preparation and pharmaceutical formulations containing said compound |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| TW513418B (en) * | 1996-07-31 | 2002-12-11 | Otsuka Pharma Co Ltd | Thiazole derivatives, their production and use |
| US6159731A (en) | 1997-02-12 | 2000-12-12 | Massachusetts Institute Of Technology | Daxx, a Fas-binding protein that activates JNK and apoptosis |
| JP4237945B2 (ja) | 1999-03-19 | 2009-03-11 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Ａｋｔ核酸、ポリペプチドおよびその使用 |
| US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| US20070167386A1 (en) | 2003-07-28 | 2007-07-19 | Osaka Industrial Promotion Organization | Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same |
| US7078064B2 (en) * | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| JP2008514635A (ja) | 2004-09-27 | 2008-05-08 | コーザン バイオサイエンシス インコーポレイテッド | 特異的キナーゼ阻害剤 |
| EP1677113A1 (en) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Method for the identification of protein-protein interactions in disease related protein networks |
| EP1983980A4 (en) * | 2006-01-25 | 2010-05-05 | Synta Pharmaceuticals Corp | THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY |
| US20070276050A1 (en) | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
| EP2044061A2 (en) * | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| US20100029619A1 (en) * | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
| AU2007333106A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
| KR20100075881A (ko) * | 2007-08-31 | 2010-07-05 | 메르크 세로노 에스. 에이. | 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도 |
| EP2271646A1 (en) | 2008-03-31 | 2011-01-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| WO2010008843A1 (en) * | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| US20110263441A1 (en) | 2008-10-15 | 2011-10-27 | Golub Todd R | Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders |
| US20110294693A1 (en) | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| US8802695B2 (en) | 2010-02-03 | 2014-08-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| WO2011097594A2 (en) | 2010-02-08 | 2011-08-11 | Kinagen, Inc. | Therapeutic methods and compositions involving allosteric kinase inhibition |
| MX345552B (es) | 2010-03-24 | 2017-02-02 | Amitech Therapeutic Solutions Inc | Compuestos heterocíclicos útiles para inhibición de cinasa. |
| CN102985418B (zh) * | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| WO2012115885A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| US20140228233A1 (en) | 2011-06-07 | 2014-08-14 | Traci Pawlowski | Circulating biomarkers for cancer |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| WO2015095059A1 (en) * | 2013-12-20 | 2015-06-25 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
-
2011
- 2011-06-30 CN CN201180033172.3A patent/CN102985418B/zh active Active
- 2011-06-30 PT PT117342204T patent/PT2588475E/pt unknown
- 2011-06-30 NZ NZ604831A patent/NZ604831A/en not_active IP Right Cessation
- 2011-06-30 ES ES11734220.4T patent/ES2543428T3/es active Active
- 2011-06-30 AU AU2011272782A patent/AU2011272782B2/en active Active
- 2011-06-30 PL PL11734220T patent/PL2588475T3/pl unknown
- 2011-06-30 JP JP2013518740A patent/JP5705314B2/ja active Active
- 2011-06-30 MX MX2012015105A patent/MX2012015105A/es active IP Right Grant
- 2011-06-30 KR KR1020137001239A patent/KR101759759B1/ko active Active
- 2011-06-30 CA CA2802743A patent/CA2802743C/en active Active
- 2011-06-30 US US13/174,459 patent/US8440665B2/en active Active
- 2011-06-30 EP EP20110734220 patent/EP2588475B1/en active Active
- 2011-06-30 SI SI201130521T patent/SI2588475T1/sl unknown
- 2011-06-30 EA EA201291273A patent/EA023040B1/ru not_active IP Right Cessation
- 2011-06-30 BR BR112012033715A patent/BR112012033715A2/pt not_active Application Discontinuation
- 2011-06-30 WO PCT/US2011/042694 patent/WO2012003387A1/en not_active Ceased
-
2012
- 2012-12-11 IL IL223556A patent/IL223556A/en active IP Right Grant
-
2013
- 2013-03-14 US US13/828,984 patent/US8927582B2/en not_active Ceased
-
2016
- 2016-08-21 IL IL247405A patent/IL247405A0/en unknown
-
2017
- 2017-01-03 US US15/397,344 patent/USRE48150E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011272782A1 (en) | 2013-01-10 |
| EP2588475B1 (en) | 2015-05-20 |
| MX2012015105A (es) | 2013-05-28 |
| CA2802743C (en) | 2019-05-07 |
| HK1184781A1 (en) | 2014-01-30 |
| EA023040B1 (ru) | 2016-04-29 |
| CN102985418B (zh) | 2015-09-09 |
| WO2012003387A1 (en) | 2012-01-05 |
| BR112012033715A2 (pt) | 2016-11-22 |
| PL2588475T3 (pl) | 2015-10-30 |
| ES2543428T3 (es) | 2015-08-19 |
| US20120004267A1 (en) | 2012-01-05 |
| IL223556A (en) | 2016-08-31 |
| CN102985418A (zh) | 2013-03-20 |
| AU2011272782B2 (en) | 2014-11-27 |
| PT2588475E (pt) | 2015-09-08 |
| KR101759759B1 (ko) | 2017-07-19 |
| CA2802743A1 (en) | 2012-01-05 |
| JP2013530240A (ja) | 2013-07-25 |
| EA201291273A1 (ru) | 2013-06-28 |
| US20130203819A1 (en) | 2013-08-08 |
| KR20130129890A (ko) | 2013-11-29 |
| EP2588475A1 (en) | 2013-05-08 |
| USRE48150E1 (en) | 2020-08-11 |
| US8440665B2 (en) | 2013-05-14 |
| JP5705314B2 (ja) | 2015-04-22 |
| IL247405A0 (en) | 2016-11-30 |
| SI2588475T1 (sl) | 2015-12-31 |
| US8927582B2 (en) | 2015-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ604831A (en) | Apoptosis signal-regulating kinase inhibitors | |
| JP2013530240A5 (enExample) | ||
| IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
| ME03723B (me) | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori | |
| AR116394A2 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| ME02322B (me) | Kinazni inhibitor koji reguliše signalni put apoptoze | |
| NZ720660A (en) | Apoptosis signal-regulating kinase inhibitors | |
| NZ709248A (en) | Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors | |
| WO2012113873A3 (en) | Organic compounds | |
| PH12018500261B1 (en) | Azole benzene derivative | |
| JP2015509543A5 (enExample) | ||
| WO2014145873A3 (en) | Heterocyclic compounds useful in the treatment of disease | |
| ZA201101891B (en) | The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide | |
| IL273000B2 (en) | Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1) | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| NO2020032I1 (no) | Avatrombopag and pharmaceutically acceptable salts thereof, particularly avatrombopag maleate (1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt | |
| NZ598750A (en) | Therapeutic agent for mood disorders | |
| JP2016534124A5 (enExample) | ||
| JP2015511632A5 (enExample) | ||
| IL263004B (en) | A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide | |
| JP2013509376A5 (enExample) | ||
| JP2016020375A5 (enExample) | ||
| EP3999181C0 (en) | POLYMORPHS OF (R)-N-(5-(5-ISOPROPYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-METHYL-2H-TETRAZOLE-5-CARBOXAMIDE | |
| MX359556B (es) | Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico. | |
| NZ595797A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2016 BY COMPUTER PACKAGES INC Effective date: 20150602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2017 BY COMPUTER PACKAGES INC Effective date: 20160601 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2018 BY COMPUTER PACKAGES INC Effective date: 20170531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2019 BY COMPUTER PACKAGES INC Effective date: 20180531 |
|
| LAPS | Patent lapsed |